ArticleFrontiers in cell and developmental biology2026
Ascorbic acid enhances
Article in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Primordial germ cells (PGCs), the precursors of sperm and oocytes, are specified from a subset of epiblast cells during the post-implantation stage of mammalian embryonic development. Over the past decade, primordial germ cell-like cells (PGCLCs) have been successfully generated Methods: To identify strategies for improving differentiation efficiency, we generated a DPPA3-mCherry PGC reporter mouse ESC line (TDM11) using CRISPR-Cas9-mediated knock-in. We implemented an embryoid body (EB)-based differentiation strategy under a non-adherent, defined culture condition, which systematically examined factors influencing PGCLC specification. PGCLC specification was assessed temporarily by flow cytometer-based quantification of DPPA3-mCherry expressing cells. Given the established role of ten-eleven translocation 1 (TET1)-mediated epigenetic regulation in PGC development, we evaluated that ascorbic acid (AA), a known activator of TET1, acts as a potent enhancer of PGCLC induction from ESCs. Results: Flow cytometric analysis revealed a substantial enrichment of DPPA3-mCherry-positive PGCLC upon AA and transferrin supplementation compared to standard EB medium. The PGCLC specification was further enhanced by combined supplementation with BMP4 and BMP8B in AA- and transferrin-supplemented basal EB medium. The DPPA3-mCherry PGCLC further characterize for the expression of other PGC-specific genes and successful derivation of embryonic germ cells. Discussion: Building upon this finding, we established a highly efficient and reproducible protocol for in vitro PGCLC differentiation from mouse embryonic stem cells (mESCs) by modulating epigenetic regulation through AA. This system provides a valuable platform for dissecting the molecular mechanism and epigenetic reprograming during early germ cell development and potential therapeutic applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.